comprimé gastro-résistant

DRUG7 trials

Sponsors

Centre Hospitalier Universitaire De Saint Etienne, Institut Gustave Roussy, Assistance Publique Hopitaux De Paris, Centre Hospitalier Regional Et Universitaire De Brest, Centre Hospitalier Universitaire Vaudois

Conditions

Acute Myocardial InfarctionAntifungal prophylaxis in patients with acute myeloid leukemiaAtrial Fibrillation Device thrombosis post-Left Atrial Appendage ClosureCastration-resistant prostate cancerPatients presenting to ENT emergencies with a unilateral sudden sensorineural hearing loss (SSNHL). SSNHL is defined according to the American ENT society guidelines criteria as a subset of SSNHL that is sensorineural in naturePhiladelphia-negative myeloproliferative neoplasms are frequent and chronic myeloid malignancies including Polycythemia Vera (PV)Primary Myelofibrosis (PMF) and Prefibrotic myelofibrosis (PreMF).acute venous thromboembolism event

Phase 2

Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms

Not yet recruitingCTIS2024-515362-13-00

Centre Hospitalier Regional Et Universitaire De Brestessential thrombocythemia (ET), Philadelphia-negative myeloproliferative neoplasms are frequent and chronic myeloid malignancies including Polycythemia Vera (PV), Primary Myelofibrosis (PMF) and Prefibrotic myelofibrosis (PreMF).

Target: 1008Updated: 2025-07-11

Phase 3

Best Antithrombotic Therapy in patients with acute Venous ThromboEmbolism while taking antiplatelets: the BAT-VTE

RecruitingCTIS2022-500974-33-00

Centre Hospitalier Universitaire De Saint Etienneacute venous thromboembolism event

Start: 2023-08-12Target: 1400Updated: 2025-04-25

A Phase III trial of acetylsalicylic acid and atorvastatin in patients with castrate-resistant prostate cancer (PEACE 4)

RecruitingCTIS2023-508072-11-00

Institut Gustave RoussyCastration-resistant prostate cancer

Start: 2019-06-26Target: 1210Updated: 2025-12-10

SERORL Effect of aspirin and folic acid for sudden sensorineural hearing loss

Not yet recruitingCTIS2024-513710-35-00

Assistance Publique Hopitaux De Parisand consists of a decrease in hearing of ≥30 decibels affecting at least 3 consecutive frequencies: 1. A history of an idiopathic and unilateral sudden decrease in hearing > 72 hours and <15 days. 2. A unilateral sensorineural hearing loss demonstrable on a pure‐tone audiogram at the time of entry into the trial. 3. No other neurological signs except the eight cranial nerve defect; no other types of hearing loss as conductive forms of hearing impairment. 4. No history of fluctuating sensorineu, occurs within a 72 hour window, Patients presenting to ENT emergencies with a unilateral sudden sensorineural hearing loss (SSNHL). SSNHL is defined according to the American ENT society guidelines criteria as a subset of SSNHL that is sensorineural in nature

Target: 142Updated: 2025-10-17

Phase 4

PTX3 genetically stratified randomized double-blinded allocation event-driven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia

Not yet recruitingCTIS2024-517211-79-00

Centre Hospitalier Universitaire VaudoisAntifungal prophylaxis in patients with acute myeloid leukemia

Target: 153Updated: 2024-10-17

Evaluation of a modified Anti-Platelet Therapy associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy (TARGET-FIRST)

CompletedCTIS2024-519854-35-00

SORIN CRM SAS (Microport CRM)Acute Myocardial Infarction

Start: 2021-06-29End: 2025-03-24Target: 695Updated: 2025-04-14

Short-Term Anticoagulation versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES study.

Not yet recruitingCTIS2025-520954-12-00

Centre Hospitalier Universite De LavalAtrial Fibrillation Device thrombosis post-Left Atrial Appendage Closure

Target: 250Updated: 2025-02-03